Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning | Zendy

Frédéric Baron | Zendy; Michael B. Maris | Zendy; Brenda M. Sandmaier | Zendy; Barry E. Storer | Zendy; Mohamed L. Sorror | Zendy; Razvan Diaconescu | Zendy; Ann E. Woolfrey | Zendy; Thomas R. Chauncey | Zendy; Mary E.D. Flowers | Zendy; Marco Mielcarek | Zendy; David G. Maloney | Zendy; Rainer Storb | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning

Author(s) -

Frédéric Baron,

Michael B. Maris,

Brenda M. Sandmaier,

Barry E. Storer,

Mohamed L. Sorror,

Razvan Diaconescu,

Ann E. Woolfrey,

Thomas R. Chauncey,

Mary E.D. Flowers,

Marco Mielcarek,

David G. Maloney,

Rainer Storb

Publication year - 2005

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2005.08.136

Subject(s) - medicine , fludarabine , total body irradiation , transplantation , graft versus host disease , multivariate analysis , hematopoietic cell , oncology , regimen , gastroenterology , hematopoietic stem cell transplantation , incidence (geometry) , malignancy , surgery , haematopoiesis , chemotherapy , cyclophosphamide , stem cell , biology , genetics , physics , optics

We have used a nonmyeloablative conditioning regimen consisting of total-body irradiation (2 Gy) with or without fludarabine (30 mg/m(2)/d for 3 days) for related and unrelated hematopoietic cell transplantation (HCT) in patients with hematologic malignancies who were not candidates for conventional HCT because of age, medical comorbidities, or preceding high-dose HCT. This approach relied on graft-versus-tumor (GVT) effects for control of malignancy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research